Skip to main content
SpringerLink
Log in

Comorbidity in Rheumatic Diseases

  • Chapter
  • First Online:
Comorbidity in Rheumatic Diseases

Abstract

Comorbidity is a condition that coexists along with the disease of interest. It could be related to the primary disease, its treatment, or be completely independent. Because certain comorbidities occur more frequently in rheumatic diseases, it is likely that the rheumatic diseases and/or their treatments could have a causative role in these comorbidities.

Comorbidities such as cardiovascular disease, malignancy, and infection impact the primary rheumatic disease in multiple ways and contribute to a higher mortality. Often they influence the patient’s quality of life and prognosis more than the primary disease itself. They add complexity to the management of the primary rheumatic disease and influence therapeutic decisions. While emerging therapies enable tighter control of disease activity, which may reduce certain comorbidities, the new treatments are accompanied by potential risk of toxicity, especially in an aging rheumatic disease population.

As care of rheumatic diseases is the focus of the rheumatologist, comorbidities are often managed suboptimally by the rheumatologist in particular and the healthcare team in general. Raising awareness regarding comorbidities among providers and patients, regular screening, tight control of rheumatic disease activity while bearing in mind the risks and benefits of treatment choices, and close collaboration between multiple disciplines including the rheumatologist, primary care physicians, and other specialists could optimize effective management of comorbidities.

This introductory chapter is intended to provide a broad overview of the most common and high-impact comorbidities encountered in rheumatic diseases and review some recommendations for their management in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

    Article  CAS  PubMed  Google Scholar 

  2. Wolfe F, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–94.

    Article  CAS  PubMed  Google Scholar 

  3. Urowitz MB, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221–5.

    Article  CAS  PubMed  Google Scholar 

  4. Aviña-Zubieta JA, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Care Res. 2008;59(12):1690–7.

    Article  Google Scholar 

  5. Maradit-Kremers H, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402–11.

    Article  PubMed  Google Scholar 

  6. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004;110(13):1774–9.

    Article  PubMed  Google Scholar 

  7. Gonzalez A, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56(11):3583–7.

    Article  PubMed  Google Scholar 

  8. Manzi S, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145(5):408–15.

    Article  CAS  PubMed  Google Scholar 

  9. Mok CC, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52(9):2774–82.

    Article  PubMed  Google Scholar 

  10. Cohen Tervaert J. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol. 2009;156(3):377–85.

    Article  CAS  Google Scholar 

  11. Tervaert JWC. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol. 2013;27(1):33–44.

    Article  Google Scholar 

  12. Ogdie A, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2014; annrheumdis-2014-205675.

    Google Scholar 

  13. Peters MJ, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34:585–92.

    Article  PubMed  Google Scholar 

  14. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev. 2011;10(5):259–66.

    Article  PubMed  Google Scholar 

  15. Papagoras C, Voulgari P, Drosos A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2012;31(4):612–20.

    Google Scholar 

  16. Nicola PJ, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412–20.

    Article  PubMed  Google Scholar 

  17. Davis JM, et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 2008;58(9):2603–11.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Robinson PC, et al. Hospital admissions associated with gout and their co-morbidities in New Zealand and England 1999–2009. Rheumatology. 2012; kes253.

    Google Scholar 

  19. Kuo C-F, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology. 2013;52(1):111–7.

    Article  PubMed  Google Scholar 

  20. Winyard PG, et al. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis. 1993;52(9):677–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Pasceri V, Yeh ET. A tale of two diseases atherosclerosis and rheumatoid arthritis. Circulation. 1999;100(21):2124–6.

    Article  CAS  PubMed  Google Scholar 

  22. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27(1):15–26.

    Article  CAS  PubMed  Google Scholar 

  23. Bacon P, Townend J. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 2001;44(12):2707–10.

    Article  CAS  PubMed  Google Scholar 

  24. Hollan I, et al. Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum. 2007;56(6):2072–9.

    Article  PubMed  Google Scholar 

  25. Sgonc R, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Investig. 1996;98(3):785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Van Paassen P, et al. Induction of endothelial cell apoptosis by IgG antibodies from SLE patients with nephropathy. Ann N Y Acad Sci. 2007;1108(1):147–56.

    Article  PubMed  CAS  Google Scholar 

  27. Peters MJ, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Care Res. 2009;61(11):1571–9.

    Article  Google Scholar 

  28. Boyer J-F, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78(2):179–83.

    Article  PubMed  Google Scholar 

  29. Masdottir B, et al. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology. 2000;39(11):1202–5.

    Article  CAS  PubMed  Google Scholar 

  30. Saevarsdottir S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology register cohorts. Arthritis Rheum. 2011;63(1):26–36.

    Article  CAS  PubMed  Google Scholar 

  31. Van Halm V, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Ann Rheum Dis. 2009;68(9):1395–400.

    Article  PubMed  Google Scholar 

  32. Bruce IN, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum. 2003;48(11):3159–67.

    Article  PubMed  Google Scholar 

  33. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum. 2009;38:372–81.

    Article  CAS  PubMed  Google Scholar 

  34. Myasoedova E, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sada K-E, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol. 2006;33(8):1545–52.

    CAS  PubMed  Google Scholar 

  36. Chung CP, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2765–75.

    Article  CAS  PubMed  Google Scholar 

  38. Kremers HM, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3450–7.

    Article  PubMed  Google Scholar 

  39. Bolten WW. Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65(1):7–13.

    Article  CAS  PubMed  Google Scholar 

  40. Panoulas VF, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47(1):72–5.

    Article  CAS  PubMed  Google Scholar 

  41. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–70.

    Article  PubMed  Google Scholar 

  42. Solomon DH, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(12):3790–8.

    Article  CAS  PubMed  Google Scholar 

  43. del RincĂ³n I, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 2003;48(7):1833–40.

    Article  PubMed  Google Scholar 

  44. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31(7):777–83.

    Article  CAS  PubMed  Google Scholar 

  45. Arts EE, et al. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis. 2014; annrheumdis-2013-204531.

    Google Scholar 

  46. Solomon DH, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum. 2015;67(6):1449–55.

    Article  CAS  Google Scholar 

  47. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63(4):522–9.

    Article  CAS  Google Scholar 

  48. Micha R, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Urowitz M, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):881–7.

    Article  CAS  Google Scholar 

  50. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34(1):70–5.

    PubMed  Google Scholar 

  51. Petri M, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93(5):513–9.

    Article  CAS  PubMed  Google Scholar 

  52. Fischer LM, et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93(2):198–200.

    Article  PubMed  Google Scholar 

  53. Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol. 2007;34(3):469–73.

    PubMed  Google Scholar 

  54. Solomon DH, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3444–9.

    Article  PubMed  Google Scholar 

  55. Dessein PH, et al. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol. 2007;34(4):681–8.

    CAS  PubMed  Google Scholar 

  56. Group EIS, Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

    Article  Google Scholar 

  57. D’Agostino RB, et al. General cardiovascular risk profile for use in primary care the Framingham heart study. Circulation. 2008;117(6):743–53.

    Article  PubMed  Google Scholar 

  58. Peters M, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–31.

    Article  CAS  PubMed  Google Scholar 

  59. Conroy R, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.

    Article  CAS  PubMed  Google Scholar 

  60. Dessein PH, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005;32(3):435–42.

    PubMed  Google Scholar 

  61. Eder L, Chandran V, Gladman DD, The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis. 2013; annrheumdis-2013-203433.

    Google Scholar 

  62. Myasoedova E, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol. 2010;22(3):342–7.

    Article  PubMed  Google Scholar 

  63. Choi HK, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173–7.

    Article  CAS  PubMed  Google Scholar 

  64. Jacobsson LT, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1213–8.

    CAS  PubMed  Google Scholar 

  65. Carmona L, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007;66(7):880–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Dixon W, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: results from the British society for rheumatology biologics register. Arthritis Rheum. 2007;56(9):2905–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Naranjo A, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):1.

    Article  CAS  Google Scholar 

  68. Symmons D, et al. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998;25(6):1072–7.

    CAS  PubMed  Google Scholar 

  69. van Halm VP, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006;8(5):1.

    Google Scholar 

  70. Smolen JS, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sharma TS, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016;5(1):e002867.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Sharma TS, Joyce E, Wasko MCM. Anti-malarials: are there benefits beyond mild disease? Curr Treatm Opt Rheumatol. 2016;2(1):1–12.

    Article  Google Scholar 

  73. Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin N Am. 1997;23(2):219–37.

    Article  CAS  Google Scholar 

  74. Atzeni F, et al. Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol. 2008;26(1 Suppl 48):S67–73.

    CAS  PubMed  Google Scholar 

  75. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1157–60.

    Article  CAS  Google Scholar 

  76. Doran MF, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300.

    Article  PubMed  Google Scholar 

  77. McLean-Tooke A, et al. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford). 2009;48(8):867–71.

    Article  CAS  Google Scholar 

  78. Curtis JR, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125–33.

    Article  CAS  PubMed  Google Scholar 

  79. Salliot C, et al. Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology. 2007;46(2):327–34.

    Article  CAS  PubMed  Google Scholar 

  80. Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649–57.

    Article  PubMed  Google Scholar 

  81. Zamora-Legoff JA, et al. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2016;29:1–5.

    Google Scholar 

  82. Cervera R, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period a comparison of early and late manifestations in a cohort of 1,000 patients. Mortality. 2003;82(5):299–308.

    Google Scholar 

  83. Bosch X, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006;15(9):584–9.

    Article  CAS  PubMed  Google Scholar 

  84. Ruiz-Irastorza G, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93.

    Article  PubMed  Google Scholar 

  86. Coyne P, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol. 2007;34(9):1832–6.

    CAS  PubMed  Google Scholar 

  87. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628–34.

    Article  CAS  PubMed  Google Scholar 

  88. Fischer A, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Carmona L, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003;30(7):1436–9.

    PubMed  Google Scholar 

  90. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.

    Article  CAS  PubMed  Google Scholar 

  91. Winthrop KL, et al. Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum. 2005;52(10):2968–74.

    Article  CAS  PubMed  Google Scholar 

  92. GĂ³mez-Reino JJ, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122–7.

    Article  PubMed  CAS  Google Scholar 

  93. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Dixon WG, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis. 2010;69(3):522–8.

    Article  CAS  PubMed  Google Scholar 

  95. Gladman DD, et al. The nature and outcome of infection in systemic lupus erythematosus. Lupus. 2002;11(4):234–9.

    Article  CAS  PubMed  Google Scholar 

  96. Kinder BW, et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007;56(8):2679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Lee HH, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156(3):486–91.

    Article  CAS  PubMed  Google Scholar 

  98. Dixon WG, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British society for rheumatology biologics register. Arthritis Rheum. 2006;54(8):2368–76.

    Article  CAS  PubMed  Google Scholar 

  99. Flendrie M, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Veetil BMA, et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res. 2013;65(6):854–61.

    Article  Google Scholar 

  101. Al S, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the united. Arthritis Rheum. 2007;57:1431–8.

    Article  Google Scholar 

  102. Segan J, et al. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumor necrosis factor alpha inhibitors. Intern Med J. 2015 Mar;45(3):310–8.

    Article  CAS  PubMed  Google Scholar 

  103. Strangfeld A, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44.

    Article  CAS  PubMed  Google Scholar 

  104. Winthrop KL, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Gilson M, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther. 2010;12(4):R145.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Puntis D, et al. Urinary tract infections in patients with rheumatoid arthritis. Clin Rheumatol. 2013;32(3):355–60.

    Article  CAS  PubMed  Google Scholar 

  107. Tishler M, et al. Increased incidence of urinary tract infection in patients with rheumatoid arthritis and secondary Sjögren’s syndrome. Ann Rheum Dis. 1992;51(5):604–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol. 2012;8(6):348–57.

    Article  CAS  PubMed  Google Scholar 

  109. Xuan D, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy – a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33:577–86.

    Article  PubMed  Google Scholar 

  110. Kim YJ, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37(2):346–50.

    Article  PubMed  Google Scholar 

  111. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65(8):983–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Lacaille D, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(8):1074–81.

    Article  PubMed  Google Scholar 

  113. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–63.

    Article  CAS  PubMed  Google Scholar 

  114. Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13(5):e1002024.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780–9.

    Article  CAS  PubMed  Google Scholar 

  116. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5–13.

    Article  CAS  PubMed  Google Scholar 

  117. Sepkowitz KA, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267(6):832–7.

    Article  CAS  PubMed  Google Scholar 

  118. Haraoui B, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD Open. 2015;1(1):e000078.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Singh JA, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum (Hoboken). 2016;68(1):1–26.

    Google Scholar 

  120. de Nard F, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol. 2015;7(3):344–61.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Hwang JP, Lok ASF. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209–19.

    Article  CAS  PubMed  Google Scholar 

  122. Calabrese LH, Cacoub PP. For patients with rheumatic disease and hepatitis C infection: the end of interferon. RMD Open. 2015;1:e000008.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Szekanecz Z, et al. Malignancies in autoimmune rheumatic diseases – a mini-review. Gerontology. 2011;57(1):3–10.

    Article  PubMed  Google Scholar 

  124. Bojinca V, Janta I. Rheumatic diseases and malignancies. Maedica (Buchar). 2012;7(4):364–71.

    Google Scholar 

  125. Turesson C, Matteson EL. Malignancy as a comorbidity in rheumatic diseases. Rheumatology (Oxford). 2013;52(1):5–14.

    Article  Google Scholar 

  126. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337–44.

    Article  PubMed  Google Scholar 

  127. Kassan SS, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89(6):888–92.

    Article  CAS  PubMed  Google Scholar 

  128. Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–11.

    Article  CAS  PubMed  Google Scholar 

  129. Apor E, et al. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014;38(9):1067–71.

    Article  PubMed  Google Scholar 

  130. Bernatsky S, et al. Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(10):1507–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Lu M, et al. Non-lymphoma hematological malignancies in systemic lupus erythematosus. Oncology. 2013;85(4):235–40.

    Article  CAS  PubMed  Google Scholar 

  132. Bernatsky S, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130–5.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Antonelli A, et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab. 2010;95(1):314–8.

    Article  CAS  PubMed  Google Scholar 

  134. Dreyer L, et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011;63(10):3032–7.

    Article  PubMed  Google Scholar 

  135. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691–6.

    Article  CAS  PubMed  Google Scholar 

  136. Smitten AL, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Simon TA, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Parikh-Patel A, et al. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009;20(6):1001–10.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Khurana R, et al. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol. 2008;35(9):1704–8.

    PubMed  Google Scholar 

  140. Andersen CL, et al. Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting. PLoS One. 2014;9(6):e99388.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  141. Rosenthal AK, et al. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis. 1993;52(7):531–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Rosenthal AK, et al. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76(5):910–4.

    Article  CAS  PubMed  Google Scholar 

  143. Onishi A, et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913–21.

    Article  PubMed  Google Scholar 

  144. Derk CT, et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006;33(6):1113–6.

    PubMed  Google Scholar 

  145. Moinzadeh P, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther. 2014;16(1):R53.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Hill CL, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.

    Article  CAS  PubMed  Google Scholar 

  147. Huang YL, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161(4):854–60.

    Article  CAS  PubMed  Google Scholar 

  148. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85(1):41–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Sigurgeirsson B, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.

    Article  CAS  PubMed  Google Scholar 

  150. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21(10):1855–9.

    CAS  PubMed  Google Scholar 

  151. Buchbinder R, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.

    Article  CAS  PubMed  Google Scholar 

  152. Sparsa A, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol. 2002;138(7):885–90.

    Article  PubMed  Google Scholar 

  153. Papageorgiou A, et al. Predicting the outcome of Sjogren’s syndrome-associated non-hodgkin’s lymphoma patients. PLoS One. 2015;10(2):e0116189.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  154. Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: risks, management, and prognosis. Rheum Dis Clin N Am. 2008; 34(4):921–33, viii.

    Google Scholar 

  155. Baimpa E, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–93.

    Article  Google Scholar 

  156. Voulgarelis M, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore). 2012;91(1):1–9.

    Article  Google Scholar 

  157. Theander E, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803.

    Article  CAS  PubMed  Google Scholar 

  158. Papageorgiou A, Voulgarelis M, Tzioufas AG. Clinical picture, outcome and predictive factors of lymphoma in Sjogren syndrome. Autoimmun Rev. 2015;14(7):641–9.

    Article  PubMed  Google Scholar 

  159. Radis CD, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995;38(8):1120–7.

    Article  CAS  PubMed  Google Scholar 

  160. Bernatsky S, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138–42.

    Article  CAS  PubMed  Google Scholar 

  161. Ognenovski VM, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004;31(9):1763–7.

    CAS  PubMed  Google Scholar 

  162. Georgescu L, et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26(6):794–804.

    Article  CAS  PubMed  Google Scholar 

  163. Usman AR, Yunus MB. Non-Hodgkin’s lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol. 1996;23(6):1095–7.

    CAS  PubMed  Google Scholar 

  164. Bachman TR, et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum. 1996;39(2):325–9.

    Article  CAS  PubMed  Google Scholar 

  165. Kameda T, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66(9):1302–9.

    Article  CAS  Google Scholar 

  166. Kamel OW, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328(18):1317–21.

    Article  CAS  PubMed  Google Scholar 

  167. Miyazaki T, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82(12):1106–9.

    Article  CAS  PubMed  Google Scholar 

  168. Scott FI, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164–72.

    Article  PubMed  Google Scholar 

  169. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.

    Article  CAS  PubMed  Google Scholar 

  170. Bongartz T, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68(7):1177–83.

    Article  CAS  PubMed  Google Scholar 

  171. Askling J, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60(11):3180–9.

    Article  CAS  PubMed  Google Scholar 

  172. Dixon WG, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British society for rheumatology biologics register. Arthritis Care Res (Hoboken). 2010;62(6):755–63.

    Article  CAS  Google Scholar 

  173. Lebrec H, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin. 2015;31(3):557–74.

    Article  CAS  PubMed  Google Scholar 

  174. Raaschou P, Frisell T, Askling J. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74(12):2137–43.

    Article  CAS  PubMed  Google Scholar 

  175. Strangfeld A, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  176. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32(11):2130–5.

    CAS  PubMed  Google Scholar 

  177. Mariette X, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895–904.

    Article  PubMed  Google Scholar 

  178. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886–95.

    Article  PubMed  Google Scholar 

  179. Mercer LK, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1087–93.

    Article  CAS  PubMed  Google Scholar 

  180. Setoguchi S, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2757–64.

    Article  CAS  PubMed  Google Scholar 

  181. Wu CY, et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther. 2014;16(5):449.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  182. Haugeberg G, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum. 2000;43(3):522–30.

    Article  CAS  PubMed  Google Scholar 

  183. Haugeberg G, et al. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum. 2000;43(12):2776–84.

    Article  CAS  PubMed  Google Scholar 

  184. Sinigaglia L, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian study group on bone mass in rheumatoid arthritis. J Rheumatol. 2000;27(11):2582–9.

    CAS  PubMed  Google Scholar 

  185. van Staa TP, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3104–12.

    Article  PubMed  Google Scholar 

  186. Laan RF, et al. Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol. 1992;31(2):91–6.

    Article  CAS  PubMed  Google Scholar 

  187. Cortet B, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol. 2000;18(6):683–90.

    CAS  PubMed  Google Scholar 

  188. Cortet B, et al. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed. 1997;64(7–9):451–8.

    CAS  PubMed  Google Scholar 

  189. Krieckaert CL, et al. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52(3):547–53.

    Article  CAS  Google Scholar 

  190. Rauner M, Hofbauer LC, Aringer M. Local and systemic bone effects of rheumatoid arthritis. Z Rheumatol. 2012;71(10):869–73.

    Article  CAS  PubMed  Google Scholar 

  191. Gough AK, et al. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis. 1994;53(1):14–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Korczowska I, Lacki JK, Hrycaj P. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients. Yonsei Med J. 2013;54(1):183–8.

    Article  CAS  PubMed  Google Scholar 

  193. Vis M, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Dimitroulas T, et al. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev. 2013;12(10):958–66.

    Article  CAS  PubMed  Google Scholar 

  195. Grossman JM, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.

    Article  Google Scholar 

  196. Svenson KL, et al. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism. 1987;36(10):940–3.

    Article  CAS  PubMed  Google Scholar 

  197. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4(5):R5.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Dessein PH, et al. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol. 2002;29(3):462–6.

    PubMed  Google Scholar 

  199. Chung CP, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196(2):756–63.

    Article  CAS  PubMed  Google Scholar 

  200. Giles JT, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol. 2015;67(3):626–36.

    Article  CAS  PubMed  Google Scholar 

  201. Wasko MC, et al. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011;63(4):512–21.

    Article  CAS  Google Scholar 

  202. Bastard JP, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.

    CAS  PubMed  Google Scholar 

  203. Popa C, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48(4):751–62.

    Article  CAS  PubMed  Google Scholar 

  204. Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2015;33(1):115–21.

    PubMed  Google Scholar 

  205. Dregan A, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130(10):837–44.

    Article  CAS  PubMed  Google Scholar 

  206. Han C, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–72.

    PubMed  Google Scholar 

  207. Dessein PH, et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol. 2004;31(5):867–74.

    CAS  PubMed  Google Scholar 

  208. Angelopoulos TP, et al. Steroid-induced diabetes in rheumatologic patients. Clin Exp Rheumatol. 2014;32(1):126–30.

    PubMed  Google Scholar 

  209. Penesova A, et al. Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors. Physiol Res. 2013;62(1):75–83.

    CAS  PubMed  Google Scholar 

  210. Toms TE, et al. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2008;10(6):R145.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  211. Hoes JN, et al. Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011;70(11):1887–94.

    Article  CAS  PubMed  Google Scholar 

  212. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis. 2011;70(11):1881–3.

    Article  CAS  PubMed  Google Scholar 

  213. den Uyl D, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. 2012;64(3):639–46.

    Article  CAS  Google Scholar 

  214. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. 2002;4(6):R12.

    Article  PubMed  PubMed Central  Google Scholar 

  215. Zonana-Nacach A, et al. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008;14(2):74–7.

    Article  PubMed  Google Scholar 

  216. Toms TE, et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther. 2009;11(4):R110.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  217. Wasko MC, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187–93.

    Article  CAS  PubMed  Google Scholar 

  218. Solomon DH, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014;66(8):1246–51.

    Article  CAS  Google Scholar 

  219. Kiortsis DN, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64(5):765–6.

    Article  CAS  PubMed  Google Scholar 

  220. Gonzalez-Gay MA, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(1):83–6.

    CAS  PubMed  Google Scholar 

  221. Tam LS, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(9):1495–8.

    Article  PubMed  Google Scholar 

  222. Chen DY, et al. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  223. Rosenvinge A, et al. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol. 2007;36(2):91–6.

    Article  CAS  PubMed  Google Scholar 

  224. Wu JJ, et al. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol. 2015;14(2):159–66.

    CAS  PubMed  Google Scholar 

  225. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  226. Schneider F, et al. Pleuropulmonary pathology in patients with rheumatic disease. Arch Pathol Lab Med. 2012;136(10):1242–52.

    Article  PubMed  Google Scholar 

  227. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24(135):102–14.

    Article  PubMed  Google Scholar 

  228. Wells AU, Denton CP. Interstitial lung disease in connective tissue disease – mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–39.

    Article  CAS  PubMed  Google Scholar 

  229. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53–82.

    Article  PubMed  Google Scholar 

  230. Nair A, Walsh SLF, Desai SR. Imaging of pulmonary involvement in rheumatic disease. Rheum Dis Clin N Am. 2015;41(2):167–96.

    Article  Google Scholar 

  231. Ngian G-S, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2012;14(5):R213.

    Article  PubMed  PubMed Central  Google Scholar 

  232. Cha S-I, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 2006;28(2):364–9.

    Article  PubMed  Google Scholar 

  233. Mondal S, et al. Interstitial lung disease as presenting feature of SLE. J Case Rep. 2014;4(1):85–7.

    Article  Google Scholar 

  234. Meyer KC, Ganesh R. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J. 2011;38(4):761–9.

    Article  CAS  PubMed  Google Scholar 

  235. Halkos ME, et al. Role of thoracic surgeons in the diagnosis of idiopathic interstitial lung disease. Ann Thorac Surg. 2005;79(6):2172–9.

    Article  PubMed  Google Scholar 

  236. Tashkin DP, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.

    Article  CAS  PubMed  Google Scholar 

  237. Keir GJ, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–9.

    Article  PubMed  Google Scholar 

  238. Schachna L, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54(12):3954–61.

    Article  PubMed  Google Scholar 

  239. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143:814–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  240. Kim EJ, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–8.

    Article  CAS  PubMed  Google Scholar 

  241. Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology. 2011;50(3):489–93.

    Article  PubMed  Google Scholar 

  242. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol. 2013;9(4):205–15.

    Article  CAS  PubMed  Google Scholar 

  243. Baker JF, Ghio AJ. Iron homoeostasis in rheumatic disease. Rheumatology (Oxford). 2009;48(11):1339–44.

    Article  CAS  Google Scholar 

  244. Remacha AF, et al. Erythroid abnormalities in rheumatoid-arthritis – the role of erythropoietin. J Rheumatol. 1992;19(11):1687–91.

    CAS  PubMed  Google Scholar 

  245. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–23.

    Article  CAS  PubMed  Google Scholar 

  246. Voulgari PV, et al. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol (Orlando, Fla.). 1999;92(2):153–60.

    Article  CAS  Google Scholar 

  247. Ferrucci L, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010;115(18):3810–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  248. Peeters HR, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis. 1996;55(3):162–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  249. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol. 2000;27(7):1668–73.

    CAS  PubMed  Google Scholar 

  250. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–99.

    Article  CAS  PubMed  Google Scholar 

  251. García Rodríguez La H-DS. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):98–101.

    Article  PubMed  Google Scholar 

  252. Bergamaschi G, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor- treatment. Haematologica. 2009;95(2):199–205.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  253. Hershko C, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica. 2005;90(5):585–95.

    CAS  PubMed  Google Scholar 

  254. Tian X-P, Zhang X. Gastrointestinal complications of systemic sclerosis. World J Gastroenterol. 2013;19(41):7062–8.

    Article  PubMed  PubMed Central  Google Scholar 

  255. Segal R, et al. Anemia, serum vitamin B12, and folic acid in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Rheumatol Int. 2004;24(1):14–9.

    Article  CAS  PubMed  Google Scholar 

  256. Bashal F. Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J. 2013;7:87–95.

    Article  PubMed  PubMed Central  Google Scholar 

  257. Owlia MB, Newman K, Akhtari M. Felty’s syndrome, insights and updates. Open Rheumatol J. 2014;8:129–36.

    Article  PubMed  PubMed Central  Google Scholar 

  258. Arlet JB, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596–601.

    Article  PubMed  PubMed Central  Google Scholar 

  259. Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol. 2011;154:289–300.

    Article  PubMed  Google Scholar 

  260. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Ther Adv Gastroenterol. 2011;4(3):177–84.

    Article  Google Scholar 

  261. Powers JM, Buchanan GR. Diagnosis and management of iron deficiency anemia. Hematol Oncol Clin North Am. 2014;28:729–45.

    Article  PubMed  Google Scholar 

  262. Lanza FL, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.

    Article  PubMed  Google Scholar 

  263. Elewaut D, Goodson N, Fleischmann R. Should we be morbid about comorbidities in the rheumatic diseases? Rheumatology (Oxford). 2013;52(1):1–2.

    Article  Google Scholar 

  264. Ranganath VK, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(10):1809–17.

    Article  Google Scholar 

  265. Wolfe F, et al. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol. 2010;37(2):305–15.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Allegheny General Hospital-Allegheny Health Network, Pittsburgh, PA, USA

    Rajesh Gopalarathinam & Mais Arwani

  2. Division of Rheumatology, Lupus Center of Excellence, West Penn Hospital, Allegheny Health Network, Pittsburgh, PA, USA

    Mary Chester M. Wasko

  3. Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, USA

    Tarun S. Sharma

Authors
  1. Rajesh Gopalarathinam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mais Arwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Chester M. Wasko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tarun S. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tarun S. Sharma .

Editor information

Editors and Affiliations

  1. Consultant Rheumatologist, Department of Rheumatology, Darent Valley Hospital, Dartford, Kent, United Kingdom

    Yasser El Miedany

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Gopalarathinam, R., Arwani, M., Wasko, M.C.M., Sharma, T.S. (2017). Comorbidity in Rheumatic Diseases. In: El Miedany, Y. (eds) Comorbidity in Rheumatic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-59963-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59963-2_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59962-5

  • Online ISBN: 978-3-319-59963-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation